Drug Trial Radar · NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
226
Planned (sponsor's estimate)
Start
Dec 5, 2023
Primary completion
Jan 24, 2028
Study completion Jan 24, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.
Conditions
- Multiple Myeloma
Interventions
AZD0305Drug
AZD0305 Investigational product
ElranatamabDrug
Module 2 Investigational product
PomalidomideDrug
Module 3 Standard of Care (background treatment)
DexamethasoneDrug
Module 3 Standard of Care (background treatment)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only)Time frame: From first dose of AZD0305 until the end of Cycle 1. Cycle 1 (the DLT assessment period is 21 days for Module 1 Group A and 28 days for Module 1 Group B, Module 2, and Module 3)
- Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From time of Informed consent to 30 days post end of treatment
- Frequency of dose modifications, dose delays, and treatment discontinuations due to AEs (Module 2 and Module 3)Time frame: From first dose of study treatment until End of treatment (EOT), assessed up to approximately 2 years (each cycle is 28 days)
Locations
46 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California · Recruiting
Research Site
Irvine, California · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Ann Arbor, Michigan · Recruiting
Research Site
St Louis, Missouri · Withdrawn
Research Site
New York, New York · Recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Fairfax, Virginia · Recruiting
Research Site
Fitzroy, Australia · Recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Nedlands, Australia · Recruiting
Research Site
Wollongong, Australia · Not yet recruiting
Research Site
Salvador, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Recruiting
Research Site
São Paulo, Brazil · Recruiting
Research Site
Nova Scotia, Canada · Not yet recruiting
Research Site
Hamilton, Ontario, Canada · Recruiting
Research Site
Ottawa, Ontario, Canada · Recruiting
Research Site
Toronto, Ontario, Canada · Not yet recruiting
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Changsha, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Shenyang, China · Recruiting
Research Site
Lille, France · Recruiting
Research Site
Nantes, France · Recruiting
Research Site
Essen, Germany · Recruiting
Research Site
Freiburg im Breisgau, Germany · Withdrawn
Research Site
Hamburg, Germany · Recruiting
Research Site
Heidelberg, Germany · Not yet recruiting
Research Site
Lübeck, Germany · Recruiting
Research Site
Nuremberg, Germany · Recruiting
Research Site
Tübingen, Germany · Not yet recruiting
Research Site
Würzburg, Germany · Recruiting
Research Site
Kashiwa, Japan · Recruiting
Research Site
Nagoya, Japan · Recruiting
Research Site
Yamagata, Japan · Recruiting
Research Site
Badalona, Spain · Recruiting
Research Site
Madrid, Spain · Recruiting
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.